- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of the trial is to evaluate the clinical anti-tumor acitivity of EMD 525797 administered as 1-hour intravenous (i.v.) infusion every 3 weeks in terms of progression free survival (PFS) time in subjects with asymptomatic or mildly symptomatic mCRPC.
Inclusion criteria
- subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (mCRPC)